The Goldman Sachs Group Begins Coverage on IQVIA (NYSE:IQV)

The Goldman Sachs Group initiated coverage on shares of IQVIA (NYSE:IQV) in a research note published on Thursday morning, Marketbeat Ratings reports. The firm issued a buy rating and a $270.00 target price on the medical research company’s stock.

Several other equities analysts have also weighed in on the stock. Guggenheim lowered shares of IQVIA from a buy rating to a neutral rating in a research report on Thursday, February 15th. SVB Leerink initiated coverage on shares of IQVIA in a report on Monday, February 26th. They issued an outperform rating and a $290.00 price objective for the company. Leerink Partnrs restated an outperform rating on shares of IQVIA in a report on Monday, February 26th. Barclays upped their price target on IQVIA from $260.00 to $265.00 and gave the stock an overweight rating in a research note on Thursday, February 15th. Finally, UBS Group raised their price objective on IQVIA from $240.00 to $300.00 and gave the company a buy rating in a research note on Thursday, February 15th. Three analysts have rated the stock with a hold rating and fourteen have issued a buy rating to the company’s stock. According to MarketBeat.com, the company has an average rating of Moderate Buy and an average target price of $258.40.

IQVIA Trading Down 0.6 %

IQVIA stock opened at $219.23 on Thursday. IQVIA has a 12 month low of $167.42 and a 12 month high of $261.73. The company has a quick ratio of 0.88, a current ratio of 0.88 and a debt-to-equity ratio of 2.02. The stock has a market cap of $39.94 billion, a P/E ratio of 29.95, a P/E/G ratio of 2.00 and a beta of 1.53. The company’s fifty day simple moving average is $230.98 and its 200-day simple moving average is $230.31.

IQVIA (NYSE:IQV) last issued its earnings results on Thursday, May 2nd. The medical research company reported $2.30 EPS for the quarter, beating analysts’ consensus estimates of $2.19 by $0.11. IQVIA had a return on equity of 29.17% and a net margin of 9.01%. The firm had revenue of $3.74 billion for the quarter, compared to the consensus estimate of $3.69 billion. As a group, sell-side analysts forecast that IQVIA will post 10.11 EPS for the current fiscal year.

Institutional Trading of IQVIA

A number of hedge funds have recently bought and sold shares of IQV. Los Angeles Capital Management LLC lifted its stake in shares of IQVIA by 17.5% in the fourth quarter. Los Angeles Capital Management LLC now owns 118,616 shares of the medical research company’s stock valued at $27,445,000 after buying an additional 17,677 shares during the period. Mitsubishi UFJ Asset Management Co. Ltd. lifted its position in IQVIA by 4.0% in the fourth quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 2,418,392 shares of the medical research company’s stock worth $532,070,000 after purchasing an additional 93,194 shares during the period. International Assets Investment Management LLC bought a new stake in IQVIA in the 4th quarter valued at $13,759,000. Schwartz Investment Counsel Inc. lifted its holdings in shares of IQVIA by 4.1% during the 4th quarter. Schwartz Investment Counsel Inc. now owns 178,690 shares of the medical research company’s stock worth $41,345,000 after acquiring an additional 7,050 shares during the period. Finally, Principal Securities Inc. acquired a new stake in shares of IQVIA during the 4th quarter valued at about $4,976,000. 89.62% of the stock is owned by institutional investors.

About IQVIA

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.